Veterinary oncology refers to the diagnosis and treatment of cancer in companion animals like dogs and cats. Veterinary oncology drugs aid in controlling tumor growth, killing cancer cells, and offering pain relief. With rising concerns about pet health among owners, the demand for veterinary oncology therapies has surged in recent years. Veterinary oncology utilizes diagnostics and therapeutics derived from human oncology and refines them to meet the unique needs of veterinary patients. Cancer is one of the leading causes of death in pets and the various oncology therapies help improve the quality as well as length of pets' lives. Chemotherapy, radiation therapy, and immunotherapy are commonly used treatment options for cancer in companion animals.
Global Veterinary Oncology Market is estimated to be valued at USD 810.5 Mn in 2025 and is expected to reach USD 1,770.6 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032.
Key Takeaways
Key players operating in the veterinary oncology market are Zoetis Inc., Elanco, VetDC, and Dechra Pharmaceuticals. Zoetis Inc. offers comprehensive treatment options for canine lymphoma, mammary tumors, osteosarcoma, and other cancers in dogs.
The increasing adoption of pets and growing pet health expenditure present significant growth opportunities for players in the Veterinary Oncology Market Demand. Pet owners are willing to spend more on therapies that can extend the lives of their furry companions. Rapid innovation in companion diagnostics and targeted therapies also enable personalized treatment of cancers in cats and dogs.
North American and European markets account for over 70% share of the global veterinary oncology market due to high disposable incomes, awareness about pet cancer treatments, and advanced veterinary healthcare infrastructure. However, the Asia Pacific region is expected to exhibit strong growth during the forecast period with economic development, rising pet adoption, and increasing access to affordable oncology drugs and therapies.
Market drivers: The key driver for veterinary oncology market is rising pet healthcare expenditure. According to the American Pet Products Association, pet owners in the U.S. spent over $30 billion on vet care in 2020 alone, reflecting both rapid growth as well as willingness to spend on furry family members' health. This increased expenditure is enabling greater access to cancer diagnostics and treatments for cats and dogs.
Market restraints: High cost of cancer therapies can limit their widespread adoption and availability in developing economies where a large proportion of the population owns pets. Limited awareness about pet cancer care in rural areas also acts as a restraint for veterinary oncology market growth currently.
Segment Analysis
The global veterinary oncology market is dominated by the companion animal segment, which accounts for over 60% share. Cancer is one of the leading causes of death in dogs and cats. Growing human-animal bonding and increasing expenditure on pet care have led to rise in demand for advanced cancer diagnosis and treatment options for companion animals. Within this segment, canine oncology sub-segment holds the major share as canines are more prone to different types of cancers as compared to felines. Prompt diagnosis and intervention improves survival rate and prognosis in pets.
Global Analysis
North America region currently dominates the global veterinary oncology market due to growing pet care expenditure, increasing pet health insurance penetration and rising incidence of pet cancer cases in the US and Canada. The region accounted for over 40% market share in 2025. Asia Pacific is projected to witness highest growth during the forecast period owing to rapidly growing pet ownership, rising per capita disposable incomes, and increasing awareness about pet cancer. Countries like India and China offer huge untapped market opportunities for players. Europe holds the second largest market position with Germany, France and UK contributing significantly to regional revenues. Focus on R&D of advanced therapies, strategic collaborations and new product launches by key players will further aid industry expansion.
Get This Report In Japanese Language
Get This Report In Korean Language
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
